(Q41735028)

8 October 2017

1 reference

title

Calcium sensitising agents in heart failure (English)

1 reference

8 October 2017

Mathew L

1

1 reference

8 October 2017

Katz SD

series ordinal

2

1 reference

8 October 2017

publication date

1 March 1998

1 reference

8 October 2017

1 reference

8 October 2017

volume

12

1 reference

8 October 2017

issue

3

1 reference

8 October 2017

page(s)

191-204

1 reference

https://scigraph.springernature.com/pub.10.2165/00002512-199812030-00003

8 October 2017

exact match

0 references

cites work

Potent stimulation of myofilament force and adenosine triphosphatase activity of canine cardiac muscle through a direct enhancement of troponin C Ca++ binding by MCI-154, a novel cardiotonic agent

1 reference

12 December 2020

Positive inotropic effects of the calcium sensitizer CGP 48506 in guinea pig myocardium

1 reference

12 December 2020

Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure

1 reference

12 December 2020

5-Methyl-6-phenyl-1,3,5,6-tetrahydro-3,6-methano-1,5-benzodiazocine-2,4-dione (BA 41899): representative of a novel class of purely calcium-sensitizing agents

1 reference

12 December 2020

Effects of pimobendan, a cardiotonic and vasodilating agent with phosphodiesterase inhibiting properties, on isolated arteries and veins of rats.

1 reference

12 December 2020

Lack of relationship between the short-term hemodynamic effects of captopril and subsequent clinical responses

1 reference

12 December 2020

Acute hemodynamic effects of nisoldipine and pimobendan in conscious pigs with chronic heart failure

1 reference

12 December 2020

Optimal treatment of heart failure in the elderly

1 reference

12 December 2020

Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial

1 reference

12 December 2020

Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure

1 reference

12 December 2020

Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators

1 reference

12 December 2020

Differential effects of d- and l-pimobendan on cardiac myofilament calcium sensitivity

1 reference

12 December 2020

Sensitization of dog and guinea pig heart myofilaments to Ca2+ activation and the inotropic effect of pimobendan: comparison with milrinone

1 reference

12 December 2020

Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction

1 reference

12 December 2020

A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure

1 reference

12 December 2020

Acute effects of intravenous UD-CG 115 BS (pimobendan) on the cardiovascular system and left ventricular pump function

1 reference

12 December 2020

Will calcium sensitizers play a role in the treatment of heart failure?

1 reference

12 December 2020

Central and peripheral components of cardiac failure

1 reference

12 December 2020

Clinical efficacy of pimobendan (UD-CG 115 BS) in patients with chronic congestive heart failure

1 reference

12 December 2020

Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium

1 reference

12 December 2020

Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart

1 reference

12 December 2020

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

12 December 2020

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

1 reference

12 December 2020

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

1 reference

12 December 2020

Positive inotropic effects of the calcium sensitizer CGP 48506 in failing human myocardium

1 reference

12 December 2020

Safety of levosimendan and other calcium sensitizers

1 reference

12 December 2020

Hemodynamic effects of intravenous pimobendan in patients with left ventricular dysfunction.

1 reference

12 December 2020

Effects of MCI-154, a calcium sensitizer, on left ventricular systolic and diastolic function in pacing-induced heart failure in the dog

1 reference

12 December 2020

Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure.

1 reference

12 December 2020

The two mechanisms of action of racemic cardiotonic EMD 53998, calcium sensitization and phosphodiesterase inhibition, reside in different enantiomers

1 reference

12 December 2020

Hemodynamic profile of the cardiotonic agent pimobendan

1 reference

12 December 2020

Mechanisms of action of calcium-sensitizing drugs

1 reference

12 December 2020

Comparison of hormonal and haemodynamic changes after long-term oral therapy with pimobendan or enalapril--a double-blind randomized study.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing

1 reference

12 December 2020

Pimobendan increases survival of cardiomyopathic hamsters

1 reference

12 December 2020

Effects of pimobendan on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy: comparison with nitroprusside

1 reference

12 December 2020

EMD 53998 acts as Ca(2+)-sensitizer and phosphodiesterase III-inhibitor in human myocardium

1 reference

12 December 2020

Stimulation of Ca++ binding and ATPase activity of dog cardiac myofibrils by AR-L 115BS, a novel cardiotonic agent

1 reference

12 December 2020

Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators

1 reference

12 December 2020

Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure.

1 reference

12 December 2020

Oral enoximone as a substitute for intravenous catecholamine support in end-stage congestive heart failure

1 reference

12 December 2020

Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure

1 reference

12 December 2020

Effects of levosimendan on myocardial contractility and oxygen consumption

1 reference

12 December 2020

Acute and long-term hemodynamic effects of pimobendan (UD-CG 115 BS) in comparison with captopril.

1 reference

12 December 2020

Disparate inotropic and lusitropic responses to pimobendan in conscious dogs with tachycardia-induced heart failure

1 reference

12 December 2020

Oxygen-saving effect of a new cardiotonic agent, MCI-154, in diseased human hearts

1 reference

12 December 2020

Treatment of chronic heart failure

1 reference

12 December 2020

Effects of pimobendan (UD-CG 115 BS) on left ventricular inotropic state in conscious dogs and in patients with heart failure

1 reference

12 December 2020

Left ventricular remodeling after acute myocardial infarction

1 reference

12 December 2020

The role of endothelium-derived vasoactive substances in the pathophysiology of exercise intolerance in patients with congestive heart failure.

1 reference

12 December 2020

Intractable heart failure despite angiotensin-converting enzyme inhibitors, digoxin, and diuretics: Long-term effectiveness of add-on therapy with pimobendan

1 reference

12 December 2020

Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction.

1 reference

12 December 2020

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

1 reference

12 December 2020

Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group

1 reference

12 December 2020

Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril

1 reference

12 December 2020

Classification of positive inotropic actions based on electrophysiologic characteristics: where should calcium sensitizers be placed?

1 reference

12 December 2020

Alterations in vasomotor tone in congestive heart failure

1 reference

12 December 2020

Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan

1 reference

12 December 2020

Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics

1 reference

12 December 2020

CGP-48506 increases contractility of ventricular myocytes and myofilaments by effects on actin-myosin reaction

1 reference

12 December 2020

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

12 December 2020

EMD 53998 sensitizes the contractile proteins to calcium in intact ferret ventricular muscle

1 reference

12 December 2020

Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments

1 reference

12 December 2020

Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group

1 reference

12 December 2020

Differential effects of the Ca2+ sensitizers caffeine and CGP 48506 on the relaxation rate of rat skinned cardiac trabeculae.

1 reference

12 December 2020

Beneficial effects of a Ca2+ sensitizer, MCI-154, on the myocardial oxygen consumption-cardiac output relation in patients with left ventricular dysfunction after myocardial infarction: comparison with dobutamine and phosphodiesterase inhibitor

1 reference

12 December 2020

The effect of digoxin on mortality and morbidity in patients with heart failure

1 reference

12 December 2020

Beneficial effect of MCI-154, a cardiotonic agent, on ischemic contractile failure and myocardial acidosis of dog hearts: comparison with dobutamine, milrinone and pimobendan

1 reference

12 December 2020

10.2165/00002512-199812030-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

8 October 2017

1007827116

0 references

1 reference